<DOC>
	<DOC>NCT01410188</DOC>
	<brief_summary>This is a study of the safety, tolerability, pharmacokinetics (measurement of drug levels in the blood), and intraocular pressure lowering effects of OPA-6566 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>diagnosis of bilateral primary openangle glaucoma diagnosis of ocular hypertension as defined in the protocol any form of glaucoma other than primary openangle glaucoma in either eye other ocular conditions as defined by the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>intraocular pressure</keyword>
</DOC>